iNOS Antibody

(Synonyms: NOS2; NOS2A; Nitric oxide synthase; inducible; Hepatocyte NOS; HEP-NOS; Inducible NO synthase; Inducible NOS; iNOS; NOS type II; Peptidyl-cysteine S-nitrosylase NOS2)
3 Cited Publications
Customer Review

Based on 3 publication(s) in Google Scholar

iNOS Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to iNOS.

For research use only. We do not sell to patients.
  • Host:

    Rabbit

  • Isotype:

    IgG

  • Application:

    WB, IHC-P, IHC-F, ICC/IF

  • Reactivity :

    Human, Mouse, Rat

  • Formulation:

    Supplied in 1*PBS (pH 7.3), 50% glycerol and 0.5% BSA. Preservative: 0.02% sodium azide.

  • Conjugation:
    Non-conjugated
3 Publications Citing Use of MCE iNOS Antibody (4)
IF
  • IF
  • IF
  • IF
  • IF

Applications

Application
WB Info
WB: Western Blot
IHC-P Info
IHC-P: Immunohistochemistry-Paraffin
IHC-F Info
IHC-F: Immunohistochemistry-Frozen
ICC/IF Info
ICC/IF: Immunocytochemistry/
Immunofluorescence
Dilution Ratio 1:500-1:1000 1:50-1:100 1:50-1:100 1:50-1:200

Product Details

Description

iNOS Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to iNOS.

  • Host Rabbit
  • Clonality Polyclonal
  • Species Reactivity
    Human, Mouse, Rat
  • Observed Molecular Weight
    Observed band size: 131 kDa Info
    Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
  • Calculated Molecular Weight Predicted band size: 131 kDa
Species Reactivity Database
Immunogen

Synthetic peptide corresponding to Human iNOS.AA range:117-166.

Sensitivity

Endogenous

Purification

affinity purified

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG

RRID

AB_3102679

Product Properties

  • Appearance

    Solution

  • Formulation

    Supplied in 1*PBS (pH 7.3), 50% glycerol and 0.5% BSA. Preservative: 0.02% sodium azide.

  • Concentration

    Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Verification Images

  • Experimental Validation Results for iNOS Antibody
    Western blot analysis of extracts from Hela (lane 2(20μg), HEK293 (lane 3(20μg) and NIH3T3 (lane 4(20μg) using iNOS (HY-P80725) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
  • Experimental Validation Results for iNOS Antibody
    Immunocytochemistry analysis of HepG2 cells labeling iNOS with iNOS antibody (HY-P80725) at 1/50 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 for 10 minutes at room temperature, then blocked with QuickBlock™ Blocking Buffer for Immunol Staining for 10 min at room temperature. Cells were then incubated with iNOS antibody (HY-P80725) at 1/50 dilution in QuickBlock™ Blocking Buffer for Immunol Staining at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).
  • Experimental Validation Results for iNOS Antibody
    Immunocytochemistry analysis of C6 cells labeling iNOS with iNOS antibody (HY-P80725) at 1/50 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 for 10 minutes at room temperature, then blocked with QuickBlock™ Blocking Buffer for Immunol Staining for 10 min at room temperature. Cells were then incubated with iNOS antibody (HY-P80725) at 1/50 dilution in QuickBlock™ Blocking Buffer for Immunol Staining at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Rabbit IgG H&L(HY-P8002, Green) was used as the secondary antibody at 1/1,000 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue).
  • Experimental Validation Results for iNOS Antibody
    Immunohistochemical analysis of paraffin-embedded Mouse lung tissue using iNOS Antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 8 minutes. The tissues were blocked in QuickBlock for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (HY-P80725, 1/100) in 4℃ overnight. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for iNOS Antibody
    Immunohistochemical analysis of paraffin-embedded Mouse lung tissue using iNOS Antibody. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 8 minutes. The tissues were blocked in QuickBlock for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (HY-P80725, 1/100) in 4℃ overnight. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.

Background

  • Function

    iNOS is an inducible nitric oxide synthase that produces nitric oxide from L-arginine and acts as a key mediator of immune activation and inflammation[1]. Mechanistically, inflammatory cells such as macrophages produce nitric oxide mainly through iNOS during inflammatory processes, where nitric oxide functions as an innate immune effector molecule[2]. iNOS expression is regulated by inflammatory signaling pathways, including PKC, NF-κB, STAT3-NF-κB interaction, and PKCδ-IRF1 signaling, which connect cytokine or LPS stimulation to nitric oxide production[2][3][4]. In disease models, dysregulated iNOS has been linked to sepsis, cancer, neurodegeneration, pain, arthritis, inflammatory bowel disease, liver fibrosis, and neurological disease models[1][5][6][7]. Compared with nNOS and eNOS, iNOS differs by stimulus-responsive expression and high nitric oxide output, whereas nNOS mainly supports neuronal signaling and eNOS supports endothelial vascular regulation[8]. However, iNOS is not solely pathological, because traumatic brain injury models showed worse outcomes after iNOS inhibition or iNOS gene deletion[9]. For experimental applications, selective iNOS inhibitors remain useful tools for testing nitric oxide-dependent mechanisms, although no iNOS inhibitor is approved for human use[1].

  • Subcellular Localization

    Cytoplasm, cytosol

  • Expression


    Tissue_specificity:It is expressed in liver, retina, bone cells, and lung airway epithelial cells. It is not expressed in platelets. It is expressed in chondrocytes (PubMed:7504305) .

    Induction:By endotoxins and cytokines. Induced by IFNG/IFN-gamma acting synergistically with bacterial lipopolysaccharides (LPS) , TNF or IL1B/interleukin-1 beta (PubMed:7504305, PubMed:7528267) . Down-regulated by zinc due to inhibition of NF-kappa-B transactivation activity (PubMed:25180171) . By oxidatively-modified low-densitity lipoprotein (LDL (ox) ) (PubMed:25417112)

  • Isoforms & Post-Translational Modification

    P35228 has 2 isomers: P35228-1: 131117 Da (predicted); P35228-2: 126749 Da (predicted).
    Polyubiquitinated; mediated by SPSB1, SPSB2 and SPSB4, leading to proteasomal degradation

  • Subunit

    Homodimer (PubMed:10074942, PubMed:10409685). Interacts with NHERF1 (PubMed:12080081). Interacts with GAPDH; induced by oxidatively-modified low-densitity lipoprotein (LDL(ox)) (PubMed:25417112). Interacts with S100A8 and S100A9 to form the iNOS-S100A8/9 transnitrosylase complex (PubMed:25417112). Interacts with SPSB1, SPSB2 and SPSB4 (PubMed:21199876). Interacts with ELOC and CUL5 in the presence of SPSB1 or SPSB2 or SPSB4 (PubMed:21199876). Forms a complex with ASL, ASS1 and HSP90AA1; the complex regulates cell-autonomous L-arginine synthesis and citrulline recycling while channeling extracellular L-arginine to nitric oxide synthesis pathway

  • SwissProt ID

    P35228

  • Gene ID
  • Synonyms

    NOS2; NOS2A; Nitric oxide synthase; inducible; Hepatocyte NOS; HEP-NOS; Inducible NO synthase; Inducible NOS; iNOS; NOS type II; Peptidyl-cysteine S-nitrosylase NOS2

  • Research Field

    Neuroscience

[1]. Cinelli MA, et al. Inducible nitric oxide synthase: Regulation, structure, and inhibition. Med Res Rev. 2020 Jan;40(1):158-189. [Content Brief]

[2]. Leppänen T, et al. Protein kinase C and its inhibitors in the regulation of inflammation: inducible nitric oxide synthase as an example. Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):37-43. [Content Brief]

[3]. Yu Z, et al. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J. 2002 Oct 1;367(Pt 1):97-105. [Content Brief]

[4]. Leppänen T, et al. Down-regulation of protein kinase Cδ inhibits inducible nitric oxide synthase expression through IRF1. PLoS One. 2013;8(1):e52741. [Content Brief]

[5]. Kolios G, et al. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology. 2004 Dec;113(4):427-37. [Content Brief]

[6]. Cinar R, et al. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. JCI Insight. 2016;1(11):e87336. [Content Brief]

[7]. Gage MC, et al. Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases. CNS Drugs. 2021 Jan;35(1):1-20. [Content Brief]

[8]. Förstermann U, et al. Nitric oxide synthases: regulation and function. Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d. [Content Brief]

[9]. Sinz EH, et al. Inducible nitric oxide synthase is an endogenous neuroprotectant after traumatic brain injury in rats and mice. J Clin Invest. 1999 Sep;104(5):647-56. [Content Brief]

View More

iNOS Antibody Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00